Stephens Reiterates “Overweight” Rating for Lifecore Biomedical (NASDAQ:LFCR)

Lifecore Biomedical (NASDAQ:LFCRGet Rating)‘s stock had its “overweight” rating reiterated by analysts at Stephens in a research report issued on Friday, Benzinga reports. They currently have a $11.00 price target on the stock.

Separately, Barrington Research decreased their target price on Lifecore Biomedical from $12.00 to $10.00 in a research report on Wednesday, January 11th.

Lifecore Biomedical Price Performance

NASDAQ LFCR opened at $1.67 on Friday. The stock has a market capitalization of $49.43 million, a P/E ratio of -0.49 and a beta of 1.11. The firm has a 50 day moving average price of $6.01. Lifecore Biomedical has a 1-year low of $1.52 and a 1-year high of $11.95. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.63 and a current ratio of 1.40.

About Lifecore Biomedical

(Get Rating)

Lifecore Biomedical, Inc engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans.

See Also

Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with's FREE daily email newsletter.